Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Acute Topics in Anti-Doping

Editor(s): Rabin O. (Montreal, Que.) 
Pitsiladis Y. (Eastbourne) 
Cover
Rabin O, Pitsiladis Y (eds): Acute Topics in Anti-Doping. Med Sport Sci. Basel, Karger, 2017, vol 62, pp 91-106
(DOI:10.1159/000465456)

Gene and Cell Doping: The New Frontier - Beyond Myth or Reality

Neuberger E.W.I. · Simon P.

Author affiliations

Department of Sports Medicine, Rehabilitation, and Disease Prevention, Johannes Gutenberg University Mainz, Mainz, Germany

Corresponding Author

Prof. P. Simon

Department of Sports Medicine, Rehabilitation and Disease Prevention

Johannes Gutenberg University Mainz

Albert Schweitzer Street 22

DE-55128 Mainz (Germany)

E-Mail simonpe@uni-mainz.de

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

The advent of gene transfer technologies in clinical studies aroused concerns that these technologies will be misused for performance-enhancing purposes in sports. However, during the last 2 decades, the field of gene therapy has taken a long and winding road with just a few gene therapeutic drugs demonstrating clinical benefits in humans. The current state of gene therapy is that viral vector-mediated gene transfer shows the now long-awaited initial success for safe, and in some cases efficient, gene transfer in clinical trials. Additionally, the use of small interfering RNA promises an efficient therapy through gene silencing, even though a number of safety concerns remain. More recently, the development of the molecular biological CRISPR/Cas9 system opened new possibilities for efficient and highly targeted genome editing. This chapter aims to define and consequently demystify the term “gene doping” and discuss the current reality concerning gene- and cell-based physical enhancement strategies. The technological progress in the field of gene therapy will be illustrated, and the recent clinical progress as well as technological difficulties will be highlighted. Comparing the attractiveness of these technologies with conventional doping practices reveals that current gene therapy technologies remain unattractive for doping purposes and unlikely to outperform conventional doping. However, future technological advances may raise the attractiveness of gene doping, thus making it easier to develop detection strategies. Currently available detection strategies are introduced in this chapter showing that many forms of genetic manipulation can already be detected in principle.

© 2017 S. Karger AG, Basel


References

  1. Friedmann T, Koss JO: Gene transfer and athletics - an impending problem. Mol Ther 2001;3:819-820.
  2. Friedmann T: How close are we to gene doping? Hastings Cent Rep 2010;40:20-22.
  3. Thompson H: Performance enhancement: superhuman athletes. Nature 2012;487:287-289.
  4. Montgomery HE, Marshall R, Hemingway H, Myerson S, Clarkson P, Dollery C, Hayward M, Holliman DE, Jubb M, World M, Thomas EL, Brynes AE, Saeed N, Barnard M, Bell JD, Prasad K, Rayson M, Talmud PJ, Humphries SE: Human gene for physical performance. Nature 1998;393:221-222.
  5. Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, Chu AY, Estrada K, Luan J, Kutalik Z, Amin N, Buchkovich ML, Croteau-Chonka DC, Day FR, Duan Y, Fall T, Fehrmann R, Ferreira T, Jackson AU, Karjalainen J, et al: Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet 2014;46:1173-1186.
  6. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Magi R, Randall JC, Winkler TW, et al: Genetic studies of body mass index yield new insights for obesity biology. Nature 2015;518:197-206.
  7. Rankinen T, Fuku N, Wolfarth B, Wang G, Sarzynski MA, Alexeev DG, Ahmetov II, Boulay MR, Cieszczyk P, Eynon N, Filipenko ML, Garton FC, Generozov EV, Govorun VM, Houweling PJ, Kawahara T, Kostryukova ES, Kulemin NA, Larin AK, Maciejewska-Karlowska A, et al: No evidence of a common DNA variant profile specific to world class endurance athletes. PLoS One 2016;11: e0147330.
  8. Bouchard C: Exercise genomics - a paradigm shift is needed: a commentary. Br J Sports Med 2015;49:1492-1496.
  9. Ritchie MD, Holzinger ER, Li R, Pendergrass SA, Kim D: Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genet 2015;16:85-97.
  10. Ehlert T, Simon P, Moser DA: Epigenetics in sports. Sports Med 2013;43:93-110.
  11. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, Ostrander EA: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007;3:e79.
  12. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ: Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682-2688.
  13. Juvonen E, Ikkala E, Fyhrquist F, Ruutu T: Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood 1991;78:3066-3069.
  14. Jelkmann W, Lundby C: Blood doping and its detection. Blood 2011;118:2395-2404.
  15. Baoutina A, Alexander IE, Rasko JE, Emslie KR: Developing strategies for detection of gene doping. J Gene Med 2008;10:3-20.
  16. Haisma HJ, de Hon O: Gene doping. Int J Sports Med 2006;27:257-266.
  17. van der Gronde T, de Hon O, Haisma HJ, Pieters T: Gene doping: an overview and current implications for athletes. Br J Sports Med 2013;47:670-678.
  18. Wells DJ: Gene doping: the hype and the reality. Br J Pharmacol 2008;154:623-631.
  19. Schneider AJ, Friedmann T: Gene doping in sports: the science and ethics of genetically modified athletes. Adv Genet 2006;51:1-110.
  20. World Anti-Doping Agency: WADA Prohibited List. Montreal, WADA, 2004, https://wada-main-prod.s3.amazonaws.com/resources/files/WADA_ Prohibited_List_2004_EN.pdf (accessed February 21, 2017).
  21. Reynolds G: Outlaw DNA. The New York Times, June 3, 2007, http://www.nytimes.com/2007/06/03/sports/playmagazine/0603play-hot.html (accessed February 21, 2017).
  22. Hayden EC: RNA interference rebooted. Nature 2014;508:443.
  23. Lundin KE, Gissberg O, Smith CI: Oligonucleotide therapies: the past and the present. Hum Gene Ther 2015;26:475-485.
  24. Thieme D: Labordiagnostische Ansätze zum Nachweis von Gendoping; in Körner S, Erber-Schropp JM (eds): Gendoping. Wiesbaden, Springer Spektrum, 2016.
  25. Gene Therapy Clinical Trials Worldwide. J Gene Med, 2016, http://www.abedia.com/wiley/years.php (accessed February 21, 2017).
  26. Kay MA: State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011;12:316-328.
  27. Nayerossadat N, Maedeh T, Ali PA: Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 2012;1:27.
  28. Mingozzi F, Buning H: Adeno-associated viral vectors at the frontier between tolerance and immunity. Front Immunol 2015;6:120.
  29. Naldini L: Gene therapy returns to centre stage. Nature 2015;526:351-360.
  30. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-158.
  31. Bryant LM, Christopher DM, Giles AR, Hinderer C, Rodriguez JL, Smith JB, Traxler EA, Tycko J, Wojno AP, Wilson JM: Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 2013;24:55-64.
  32. Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK: A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther 2015;23:192-201.
  33. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Cherel Y, Casadevall N, Samulski RJ, Moullier P: Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 2004;103:3303-3304.
  34. Gao G, Lebherz C, Weiner DJ, Grant R, Calcedo R, McCullough B, Bagg A, Zhang Y, Wilson JM: Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 2004;103:3300-3302.
  35. Snyder RO, Flotte TR: Production of clinical-grade recombinant adeno-associated virus vectors. Curr Opin Biotechnol 2002;13:418-423.
  36. Trounson A, McDonald C: Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 2015;17:11-22.
  37. World Health Organization: Haematopoietic Stem Cell Transplantation HSCtx. Geneva, WHO, 2016, http://www.who.int/transplantation/hsctx/en/ (accessed February 21, 2017).
  38. Biasco L, Baricordi C, Aiuti A: Retroviral integrations in gene therapy trials. Mol Ther 2012;20:709-716.
  39. Mullard A: EMA greenlights second gene therapy. Nat Rev Drug Discov 2016;15:299.
  40. Gaspar HB: Gene therapy for ADA-SCID: defining the factors for successful outcome. Blood 2012;120:3628-3629.
  41. Holzinger A, Barden M, Abken H: The growing world of CAR T cell trials: a systematic review. Cancer Immunol Immunother 2016;65:1433-1450.
  42. Dimmeler S, Ding S, Rando TA, Trounson A: Translational strategies and challenges in regenerative medicine. Nat Med 2014;20:814-821.
  43. Osborne H, Anderson L, Burt P, Young M, Gerrard D: Australasian College of Sports Physicians-position statement: the place of mesenchymal stem/stromal cell therapies in sport and exercise medicine. Br J Sports Med 2016;50:1237-1244.
  44. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676.
  45. Matsu-Ura T, Sasaki H, Okada M, Mikoshiba K, Ashraf M: Attenuation of teratoma formation by p27 overexpression in induced pluripotent stem cells. Stem Cell Res Ther 2016;7:30.
  46. Goodchild J: Therapeutic oligonucleotides. Methods Mol Biol 2011;764:1-15.
  47. Kohler M, Schanzer W, Thevis M: RNA interference for performance enhancement and detection in doping control. Drug Test Anal 2011;3:661-667.
  48. Kozomara A, Griffiths-Jones S: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011;39:D152-D157.
  49. Friedman RC, Farh KKH, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
  50. Kanasty R, Dorkin JR, Vegas A, Anderson D: Delivery materials for siRNA therapeutics. Nat Mater 2013;12:967-977.
  51. Meade BR, Gogoi K, Hamil AS, Palm-Apergi C, van den Berg A, Hagopian JC, Springer AD, Eguchi A, Kacsinta AD, Dowdy CF, Presente A, Lonn P, Kaulich M, Yoshioka N, Gros E, Cui XS, Dowdy SF: Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat Biotechnol 2014;32:1256-1261.
  52. Querbes W, Bogorad RL, Moslehi J, Wong J, Chan AY, Bulgakova E, Kuchimanchi S, Akinc A, Fitzgerald K, Koteliansky V, William GW: Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood 2012;120:1916-1922.
  53. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012;337:816-821.
  54. Urnov F: The domestication of Cas9. Nature 2016;529:468-469.
  55. Gaj T, Gersbach CA, Barbas CF 3rd: ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013;31:397-405.
  56. Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, Sun Y, Bai Y, Songyang Z, Ma W, Zhou C, Huang J: CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 2015;6:363-372.
  57. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng ZL, Joung JK: High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 2016;529:490-495.
  58. Tsai SQ, Joung JK: Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet 2016;17:300-312.
  59. Caplan AL, Parent B, Shen M, Plunkett C: No time to waste - the ethical challenges created by CRISPR: CRISPR/Cas, being an efficient, simple, and cheap technology to edit the genome of any organism, raises many ethical and regulatory issues beyond the use to manipulate human germ line cells. EMBO Rep 2015;16:1421-1426.
  60. Bosley KS, Botchan M, Bredenoord AL, Carroll D, Charo RA, Charpentier E, Cohen R, Corn J, Doudna J, Feng GP, Greely HT, Isasi R, Ji WZ, Kim JS, Knoppers B, Lanphier E, Li JS, Lovell-Badge R, Martin GS, Moreno J, et al: CRISPR germline engineering - the community speaks. Nat Biotechnol 2015;33:478-486.
  61. Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M, Greely HT, Jinek M, Martin GS, Penhoet E, Puck J, Sternberg SH, Weissman JS, Yamamoto KR: A prudent path forward for genomic engineering and germline gene modification. Science 2015;348:36-38.
  62. Lee SJ: Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet 2007;23:475-477.
  63. Mattsson CM, Wheeler MT, Waggott D, Caleshu C, Ashley EA: Sports genetics moving forward: lessons learned from medical research. Physiol Genomics 2016;48:175-182.
  64. High K, Gregory PD, Gersbach C: CRISPR technology for gene therapy. Nat Med 2014;20:476-477.
  65. Camporesi S, McNamee MJ: Performance enhancement, elite athletes and anti doping governance: comparing human guinea pigs in pharmaceutical research and professional sports. Philos Ethics Humanit Med 2014;9:4.
  66. Robinson N, Saugy M, Vernec A, Pierre-Edouard S: The athlete biological passport: an effective tool in the fight against doping. Clin Chem 2011;57:830-832.
  67. Pitsiladis YP, Durussel J, Rabin O: An integrative “omics” solution to the detection of recombinant human erythropoietin and blood doping. Br J Sports Med 2014;48:856-861.
  68. Zorzoli M, Pipe A, Garnier PY, Vouillamoz M, Dvorak J: Practical experience with the implementation of an athlete's biological profile in athletics, cycling, football and swimming. Br J Sports Med 2014;48:862-866.
  69. Friedmann T, Rabin O, Frankel MS: Ethics. Gene doping and sport. Science 2010;327:647-648.
  70. Durussel J, Haile DW, Mooses K, Daskalaki E, Beattie W, Mooses M, Mekonen W, Ongaro N, Anjila E, Patel RK, Padmanabhan N, McBride MW, McClure JD, Pitsiladis YP: The blood transcriptional signature of recombinant human erythropoietin administration and implications for anti-doping strategies. Physiol Genomics 2016;48:202-209.
  71. Lasne F, Martin L, de Ceaurriz J, Larcher T, Moullier P, Chenuaud P: “Genetic doping” with erythropoietin cDNA in primate muscle is detectable. Mol Ther 2004;10:409-410.
  72. Bidlingmaier M, Suhr J, Ernst A, Wu Z, Keller A, Strasburger CJ, Bergmann A: High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clin Chem 2009;55:445-453.
  73. Kohler M, Thomas A, Walpurgis K, Schanzer W, Thevis M: Mass spectrometric detection of siRNA in plasma samples for doping control purposes. Anal Bioanal Chem 2010;398:1305-1312.
  74. Thomas A, Walpurgis K, Delahaut P, Kohler M, Schanzer W, Thevis M: Detection of small interfering RNA (siRNA) by mass spectrometry procedures in doping controls. Drug Test Anal 2013;5:853-860.
  75. Beiter T, Zimmermann M, Fragasso A, Armeanu S, Lauer UM, Bitzer M, Su H, Young WL, Niess AM, Simon P: Establishing a novel single-copy primer-internal intron-spanning PCR (spiPCR) procedure for the direct detection of gene doping. Exerc Immunol Rev 2008;14:73-85.
  76. Baoutina A, Coldham T, Fuller B, Emslie KR: Improved detection of transgene and nonviral vectors in blood. Hum Gene Ther Methods 2013;24:345-354.
  77. Ni W, Le Guiner C, Gernoux G, Penaud-Budloo M, Moullier P, Snyder RO: Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: implications for gene doping. Gene Ther 2011;18:709-718.
  78. Beiter T, Zimmermann M, Fragasso A, Hudemann J, Niess AM, Bitzer M, Lauer UM, Simon P: Direct and long-term detection of gene doping in conventional blood samples. Gene Ther 2011;18:225-231.
  79. Neuberger EW, Perez I, Le Guiner C, Moser D, Ehlert T, Allais M, Moullier P, Simon P, Snyder RO: Establishment of two quantitative nested qPCR assays targeting the human EPO transgene. Gene Ther 2016;23:330-339.
  80. Moser DA, Braga L, Raso A, Zacchigna S, Giacca M, Simon P: Transgene detection by digital droplet PCR. PLoS One 2014;9:e111781.
  81. Goodwin S, McPherson JD, McCombie WR: Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet 2016;17:333-351.
  82. Rabbani B, Nakaoka H, Akhondzadeh S, Tekin M, Mahdieh N: Next generation sequencing: implications in personalized medicine and pharmacogenomics. Mol BioSyst 2016;12:1818-1830.
  83. Willems S, Fraiture MA, Deforce D, De Keersmaecker SC, De Loose M, Ruttink T, Herman P, Van Nieuwerburgh F, Roosens N: Statistical framework for detection of genetically modified organisms based on next generation sequencing. Food Chem 2016;192:788-798.
  84. Favre D, Provost N, Blouin V, Blacho G, Cherel Y, Salvetti A, Moullier P: Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther 2001;4:559-566.
  85. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, et al: Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.
  86. Vogel G: A race to the starting line. Science 2004;305:632-635.
  87. Report on Proceedings under the World Anti-Doping Code and the USADA Protocol. Colorado Springs, USADA, 2012, https://d3epuodzu3wuis.cloudfront.net/ReasonedDecision.pdf (accessed February 21, 2017).
  88. Goldman B, Bush PJ, Klatz R: Death in the Locker Room: Steroids & Sports. South Bend, Icarus Press, 1984.
  89. Connor J, Woolf J, Mazanov J: Would they dope? Revisiting the Goldman dilemma. Br J Sports Med 2013;47:697-700.
  90. Scott CT, DeFrancesco L: Gene therapy's out-of-body experience. Nat Biotechnol 2016;34:600-607.
  91. EMA: Glybera Summary of Product Characteristics. 2016, http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/002145/WC500135472.pdf (accessed February 21, 2017).
  92. Tentori L, Graziani G: Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? Pharmacol Res 2007;55:359-369.
  93. Morkeberg J: Blood manipulation: current challenges from an anti-doping perspective. Hematology Am Soc Hematol Educ Program 2013;2013:627-631.
  94. Thevis M, Kuuranne T, Walpurgis K, Geyer H, Schanzer W: Annual banned-substance review: analytical approaches in human sports drug testing. Drug Test Anal 2016;8:7-29.

Article / Publication Details

First-Page Preview
Abstract of The Anti-Doping Science

Published online: June 02, 2017
Cover Date: 2017

Number of Print Pages: 16
Number of Figures: 2
Number of Tables: 1

ISBN: 978-3-318-06043-0 (Print)
eISBN: 978-3-318-06044-7 (Online)